我国晚期非小细胞肺癌化疗作用现状分析  

The Present Status Chemotherapy for Advanced NSCLC in China

作　　者：臧爱华[1] 于丁[1] 柯玉华[1] 王志军[1] 冉凤鸣[1] 胡胜[1] 

机构地区：[1]湖北省肿瘤医院,湖北武汉430079

出　　处：《中国肿瘤》2005年第9期611-613,共3页China Cancer

摘　　要：[目的]评价我国非小细胞肺癌的化疗现状。[方法]收集符合分析的国内文献54篇,累计病例2485,每个研究的中位病例数为37;随访研究13个,中位随访时间为9个月;采用SPSS统计分析治疗反应率,治疗方案、周期、费用与疗效的关系。[结果]平均有效率为46.3%,95%CI为43%～50%。方案以GP方案疗效最好,而CAP方案最低(51.4%vs30.5%,χ2=11.3,P<0.05),采用新药的方案要优于以前的方案;4周期化疗方案可能优于2周期方案,但无统计学差异;疗效与医疗费用存在关系,但缺乏对照研究。[结论]我国NSCLC化疗效果与国外资料相似,但因病例数目少,资料不全面,统计方法落后,难以得出可靠的、令人信服的结论。[Purpose]To evaluate the present status of chemotherapy for advanced non-small cell lung cancer (NSCLC) in China.[Methods]Fifty-four domestic literatures were collected for analysis. A total of was 2 485 patients was in the literatus with median 37 number in 1 literatare; The median period of follow-up was 9 months in 13 literature.The response rate, regimens, courses, costs and efficacy was assessed by SPSS software. [Results] The averaged response rate was 46.3%( 95%CI=43%~50%). GP regimen was the highest response rate to chemotherapy but CAP regimen was the lowest one(51.4% vs 30.5%, χ2=11.3, P<0.05).The regimens with new agents were better than that with common agents. Four cycles of chemotherapy might be more appropriate than 2 cycles although there were no significant difference.Chemotherapeutic cost was correlated to response rate,however,well-controlled studies were required to adequately evaluate. [Conclusions]The efficacy of chemotherapy for NSCLC in China is similar to foreign literatures. However,it is hard to make a reliable conclusion because of small samples,incompletive data and simple statistic assay.

关 键 词：非小细胞肺癌 化学疗法 

分 类 号：R734.2[医药卫生—肿瘤]